| abstract |
Disclosed herein are methods of treating inflammation by administering to a patient an HIV-protease inhibitor. While protease inhibitors are know for their capacity to prevent or significantly hinder the cleavage of proteins that would otherwise become smaller viral particles, certain of these inhibitors may also be employed in the treatment of inflammation and diseases in which an inflammatory response is evident. Further methods are directed to the treatment of disease conditions in which it may be advantageous to down-modulate NF-κB cell signal transduction. |